Genenta cashes in 7 mln euros in a Series B investment round, reaching 17 mln euros in total capital raised

Genenta cashes in 7 mln euros in a Series B investment round, reaching 17 mln euros in total capital raised
Genenta Science, a biotech company committed to the development and commercialization of a hematopoietic stem cell gene therapy for tumors treatment, cashed in 8.4 million dollars (or 7 million euros) in a new investment round (Series B) led by Italian, British, and Swiss private investors, family offices and business angels, Series A investors and Board Members (scarica qui il comunicato stampa). Genenta banked a Series A 10 million euros financing in March 2015 raised among a group of private investors gathered by Banca Esperia among its private banking clients (see here a previous post by BeBeez). So the company has been raising a total of 20.4 million dollars (or 17 million euros) since its foundation. Guido Guidi was appointed as a Board Member. D in Genenta, being a former Head of Pharma Region Europe and previously as Head of Oncology Europe at Novartis where he developed and launched several blockbuster products (Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge, Zometa, Femara e Glivec). He was also a member of the Novartis Pharma Executive Committee (PEC) and Chairman of the Novartis European Executive Committee (EEC). Prof. Kenneth C. Anderson is now part of the Scientific Advisory Board led by Luigi Naldini, Genenta’s co-founder, director of the Regenerative Medicine Division of the San Raffaele Hospital and director of theIstituto San Raffaele Telethon per la Terapia Genica. Prof. Anderson directs the Lebow Institute[...]

Articoli correlati

  • Directa Plus jumps 41% in first day of trading on Aim London30 maggio 2016 Directa Plus jumps 41% in first day of trading on Aim London Graphene-based products supplier Directa Plus shares rose by 41% closing at 105.5 pence last Friday May 27th in the first day of trading on Aim London (download here the press release). The company had announced its intention to listing about ten days ago (see ahere a previous post by BeBeez) ...
  • All Italian venture capital and business angels’ deals in 201511 gennaio 2016 All Italian venture capital and business angels’ deals in 2015 Year 2015 was quite an intensive period as for venture capitalists and business angels in Italy, BeBeez's database shows (download here a table with data an links to BeBeez's posts). More in detail BeBeez counted 86 deals as for new investments and capital increases last year for a total amoun...
  • Italy’s leading certification service provider Rina to buy British Edif Group25 maggio 2016 Italy’s leading certification service provider Rina to buy British Edif Group Rina spa, the parent company of the Rina Group, Italy’s leading E-TIC (Engineering, Testing, Inspection, Certification) service provider. will buy the entire capital of British testing and inspection firm Edif Group Limited for about 150 million euros, MF Milano Finanza wrote yesterday and the co...
  • Recordati group to buy Italchimici from Progressio and Idea Capital Funds1 giugno 2016 Recordati group to buy Italchimici from Progressio and Idea Capital Funds Funds managed by  Italy's private equity firms Progressio  sgr and Idea Capital Funds sgr striked a very good deal yesterday announcing the sale of their portfolio company Italchimici to Italian pharaceutical group Recordati (see here the press release). less than one year from their investment a...
  • Come si scovano le startup giuste in Italia. Ricerca Leanus-Milano Finanza16 marzo 2016 Come si scovano le startup giuste in Italia. Ricerca Leanus-Milano Finanza Con ricavi che in media sono di 94 mila euro all'anno, un ebitda negativo del 30%, investimenti per 53 mila euro e debiti finanziari per 23 mila euro, l'identikit della startup innovativa italiana media è impietoso. I dati sono il risultato di una ricerca condotta dalla società di business inform...

Lascia un Commento

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *

È possibile utilizzare questi tag ed attributi XHTML: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>